SEC Form 4 · accession 0001171843-15-006473
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthias Alder
Officer — EVP, Business Dev. & Licensing
Period of report
Jun 30, 2015
Accepted (ET)
Nov 20, 2015 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, Class A (ESPP)F1,F2 | Jun 30, 2015 | A | 523 | $13.37 | A | 523 | D | |
| Common Stock, Class A (ESPP)F3,F4 | Sep 30, 2015 | A | 413 | $14.52 | A | 936 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2015 through June 30, 2015. This transaction is exempt under Rule 16(b)-3(c).
- F2In accordance with the ESPP, these shares were purchased at 85% of the closing price of the issuer's common stock on April 1, 2015.
- F3The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's ESPP for the period July 1, 2015 through September 30, 2015. This transaction is exempt under Rule 16(b)-3(c).
- F4In accordance with the ESPP, these shares were purchased at 85% of the closing price of the issuer's common stock on July 1, 2015.